Evidence map›Paper›PMID 38724713›Full record

ArticleBiochemical genetics2025

ARHGAP17 Inhibits Hepatocellular Carcinoma Progression by Inactivation of Wnt/β-Catenin Signaling Pathway.

Sirui Fan, Hongqing Zhao, Cheng Li, Xing Chen, Mingjie Sun, Fengyang Chen, Chao Long, Yinghui Zhou, Boyuan Nan, Hao Zhao and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sirui FanGraduate Training Base, General Hospital of Northern Theater Command of Jinzhou Medical University, Shenyang, 110016, Liaoning, China.
Hongqing ZhaoGraduate School, Jinzhou Medical University, Jinzhou, 121000, Liaoning, China.
Cheng LiDepartment of Immunology, The College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
Xing ChenDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
Mingjie SunDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
Fengyang ChenDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
Chao LongDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
Yinghui ZhouDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
Boyuan NanDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
Hao ZhaoDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
Wei ZhangDepartment of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China. zhang_wei_1980@163.com.

Funding

Natural Science Foundation of Liaoning Province 2019-ZD-1062the Joint Program of Key R&D Programs of Liaoning Province 2020JH2/10300168the R&D PROGRAMME FOR MAJOR technological innovations of Shenyang City 19-112-4-081
6 · The paper itself

Abstract

As a member of Rho GAPs family, Rho GTPase-Activating Protein 17 (ARHGAP17) regulates cytoskeletal recombination, cell polarity, cell proliferation and cell migration. ARHGAP17 is identified as a tumor suppressor in numerous cancer types. Current study intends to examine ARHGAP17 expression and its possible influence on the progression of hepatocellular carcinoma (HCC). ARHGAP17 expression in HCC cells was verified by RT-PCR and western blot. The proliferation and invasion of HCC cells were evaluated by CCK8 assay and transwell assay, respectively. The mRNA expression of ARHGAP17, PCNA, E-cadherin, N-cadherin, β-catenin, GSK-3β, Axin1, and APC were detected by RT-PCR. The protein expression of ARHGAP17, PCNA, E-cadherin, N-cadherin, β-catenin, p-β-catenin, GSK-3β, p-GSK-3β, Axin1, and APC were detected by western blot. ARHGAP17 staining was evaluated by immunohistochemistry and immunofluorescence. ARHGAP17 expression decreased significantly in HCC tumors and HCC cells after EMT. In response to overexpression of ARHGAP17, the capacities of HCC cell proliferation and invasion were reduced significantly, which were also confirmed by tumorigenesis experiments in vivo. With overexpression of ARHGAP17 in HCC cells, the p-GSK3β/GSK3β decreased, while the p-β-catenin/β-catenin, Axin1 and APC increased. In conclusion, ARHGAP17 inhibits HCC progression by inactivating the Wnt/β-catenin signaling pathway.

Indexed as

beta CateninCarcinoma, HepatocellularGTPase-Activating ProteinsLiver NeoplasmsWnt Signaling PathwayAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticGlycogen Synthase Kinase 3 betaHumansMaleMicebeta CateninCTNNB1 protein, humanGlycogen Synthase Kinase 3 betaGTPase-Activating ProteinsARHGAP17EMTHepatocellular carcinomaWnt/β-catenin

Identifiers

PMID38724713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.